ORGANIZATION

EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies

October 26, 2018
Amid the emergence of innovative-but-pricey therapies that could cure diseases, Japan should work to evaluate their long-term benefits, and look at a new funding model that would allow split payments over multiple financial years so as to cope with cases…

To read the full story

ORGANIZATION

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…